Conference
Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.
Abstract
626
Background: The IMDC risk score is a valid and simple tool to prognosticate patients (pts) with metastatic renal cell carcinoma (mRCC). Some non-VHL common genomic alterations may be associated with outcomes. We therefore assessed the prognostic value of most commonly mutated genes in mRCC beside VHL overall, and within IMDC risk groups. Methods: We identified patients treated at Dana-Farber Cancer Institute (n = 65) or …
Authors
Bosse D; Xie W; Lalani A-KA; de Velasco G; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Rathmell K; Heng DYC
Volume
36
Pagination
pp. 626-626
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2018.36.6_suppl.626
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X